

**A+ Science Invest AB announces an agreement with
Janssen Pharmaceutica on the use of galantamine in obstructive sleep apnoea**

A+ Science Invest AB of Sweden announces an agreement with Janssen Pharmaceutica whereby Janssen has acquired the exclusive worldwide license to certain A+ intellectual property rights specifically the development and commercialization of galantamine for the treatment of obstructive sleep apnoea (OSA). Janssen Pharmaceutica N.V. of Belgium is an affiliate of Johnson & Johnson (NYSE: JNJ) of New Brunswick, N.J.

Janssen is currently developing galantamine for the treatment of Alzheimer's disease and related dementias under an agreement with Shire Pharmaceutical of the UK.

Twenty million Americans suffer from OSA, a condition in which the patient stops breathing for extended periods of time during sleep. As many as 6.4 million OSA sufferers may require medical intervention, but only 400,000 have been diagnosed and treated, at a cost of nearly USD 16 billion.

Apart from surgical intervention, which is only 50% effective and is associated with a painful recovery period, the predominant treatment is Continuous Positive Airway Pressure (CPAP). However, the inconvenience and discomfort of this procedure results in poor patient compliance.

A+ Science Invest AB (www.a-plusscience.se), founded in 1997, is involved in the development of academic research with commercial potential. At present, most of the developments emanate from the Faculty of Medicine and the Faculty of Science at Göteborg University, Sweden. The company's current project portfolio consists of over 40 patents and patent applications and derives primarily from specialized research in biomedicine and medical technology.

For further information contact:

Jan Ahlström, A+ Science Invest AB

Phone: +46 31 778 2131; Fax +46 31 778 2140;

E-mail: jan.ahlstrom@a-plusscience.se